“Has everyone forgotten the crazy loan which cytodyn just took out? Doesn’t it stand to reason that the company is expecting some cash in shortly or maybe some has already arrived in order to pay off this loan?”

This is the 3rd financing deal this year between and CYDY. After the second deal, which was also for $28 million, investors were making similar statements that you are now: CYDY would only agree to a such terms because good financing or revenue is close. Well, that second deal was executed on July 29th, 2020.

The recent scheduling of the CC and the Phillippines announcing expedited approval of COVID19 therapeutics days later are likely not related. The S/C data from the 75% point is not ready to be submitted to the Phillippines for approval, but it may be by the end of the month if NP decides to unblind the data at 28 days.

IMO, I believe strongly that NP will unblind the 28 day data and submit it for an EUA if the mortality rate is reduced and the reduction is statically significant. Why do I believe this? Because the recent $28 million raised won’t last past January considering that publicly, it appears CYDY still owes $27 million or so to Samsung. Maybe we hear at the CC that Samsung granted a delay in the payments. Who knows, but I believe NP is banking on the 75% data being good and the SP raising after, resulting in financing becoming easier.